Bristol-Myers Squibb Faces Suit Over Serzone
Dow Jones -

04/17/02 - Bristol -Myers Squibb Co . Inc. (BMY) is the target of a lawsuit over damages allegedly suffered from use of its Serzone antidepressant.

In a press release Wednesday, Kenneth B. Moll & Associates, the law firm representing the plaintiffs, said it seeks a court order forcing Bristol -Myers to stop the manufacture and sale of Serzone, as well as a recall.

Serzone is an antidepressant that inhibits serotonin reuptake and blocks one type of serotonin receptor. It is prescribed for depression that causes anxiousness.

The lawsuit also seeks to inform the public that Serzone users are at an increased risk of liver complications, provide compensation to all victims for death and personal injuries, provide a medical monitoring fund for Serzone users and reimburse monies paid for Serzone.

The law firm said that over 109 cases of serious liver injuries allegedly associated with Serzone have been reported.

In at least 23 cases, Serzone users experienced liver failure and 16 underwent a liver transplant and/or died, it said.

<< previous page